SCHEMBL20113952

SCHEMBL20113952

Cc1cc(C=O)c(C=O)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 8/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
MPI P34949 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 2/20 0.37
ERN1 O75460 2/20 0.35
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34
GRIA4 P48058 1/20 0.34
GAA P10253 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17408855 0.82 BCHE (0.37) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL10735089 0.77 CYP3A4 (0.59) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL9681854 0.74 ALDH1A1 (0.39) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL30705516 0.74 ALDH1A1 (0.39) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL9681760 0.74 ALDH1A1 (0.39) CYP3A4ALDH1A1KDM4EMAPTTSHR
SCHEMBL20113675 0.74 ALDH1A1 (0.34) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL446933 0.70 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL9798631 0.70 EGFR (0.34) BCHEACHEMAOBKCNJ1
SCHEMBL1697663 0.70 KCNJ1 (0.37) BCHEACHEMAOBKCNJ1
SCHEMBL30600409 0.70 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3060563-B1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2018-05-02 EP disclosed